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Following publication of the original article \[[@CR1]\], the authors identified some minor errors in image-typesetting in Figs. [2](#Fig1){ref-type="fig"} and [3](#Fig2){ref-type="fig"}; specifically in Fig. [2](#Fig1){ref-type="fig"}a, and Fig. [3](#Fig2){ref-type="fig"}b and Fig. [3](#Fig2){ref-type="fig"}d (corrected labels beneath the quantitative histograms). The correct figure is given below. All correction had no any effect to the final conclusion. Fig. 2Cell morphology in sg1-MSI2, sg2-MSI2 and scramble transfected AsPC-1 and BxPC-3 cells with or without EGF (50 ng/ml) treatment. **a** and **b** Under EGF treatment, the fibroblastoid-like phenotype in AsPC-1 (**a**) and BxPC-3 (**b**) cells in scramble, sg1-MSI2 and sg2-MSI2 groupsFig. 3MSI2 silencing inhibited EGF-induced Cell invasion and migration in PC cells. **a** and **b** Cell invasion (**a**) and migration (**b**) in sg1-MSI2, sg2-MSI2 and scramble transfected AsPC-1 cells with or without EGF (50 ng/ml) treatment. **c** and **d** Cell invasion (**c**) and migration (**d**) in sg1-MSI2, sg2-MSI2 and scramble transfected BxPC-3 cells with or without EGF (50 ng/ml) treatment. Bars indicate ± S.E.\*, *P* \< 0.05; \*\*, *P* \< 0.01 compared with the control
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